肝窦内皮细胞在肝脏疾病中的作用及相关治疗药物研究进展  

Advances in Research on the Role of Liver Sinusoidal Endothelial Cell in Liver Diseases and Related Therapeutic Drugs

作　　者：钱家龙 周梦泽 胡庆华 QIAN Jialong;ZHOU Mengze;HU Qinghua(School of Pharmacy,China Pharmaceutical University,Nanjing 211198,China;School of Life Science and Technology,China Pharmaceutical University,Nanjing 211198,China)

机构地区：[1]中国药科大学药学院,江苏南京211198 [2]中国药科大学生命科学与技术学院,江苏南京211198

出　　处：《药学进展》2024年第11期813-822,共10页Progress in Pharmaceutical Sciences

基　　金：江苏省自然科学基金(No.BK20231022)。

摘　　要：肝窦内皮细胞是肝脏最大的非实质细胞群,作为外周血液进入肝脏的第一道防线,其在生理条件下积极维持肝窦微环境稳态。在病理状态下,肝窦内皮细胞受到肝窦内其他细胞和外周免疫细胞异常激活,通过多种方式调控肝脏疾病的发生与进展。大量研究表明,减轻肝窦内皮细胞功能障碍是临床治疗急性和慢性肝脏疾病的有效策略。综述了肝窦内皮细胞在肝脏疾病中的作用,并对相关治疗药物研究进行简介,旨在为肝脏疾病发病机制的阐明与临床治疗手段的开发提供思路与参考。Liver sinusoidal endothelial cells(LSECs)are the largest non-parenchymal cell population in the liver.As the first line of defense for peripheral blood entering the liver,LSECs actively maintain the homeostasis of liver sinusoidal microenvironment under physiological conditions.In the pathological states,LSECs are abnormally activated by other cells in the hepatic sinuses and peripheral immune cells,regulating the occurrence and progression of liver diseases through various ways.Numerous studies have shown that mitigating the dysfunction of LSECs is an effective strategy for the clinical treatment of acute and chronic liver diseases.This article reviews the role of LSECs in liver diseases and introduces the research on related therapeutic drugs,aiming to provide insights and reference for elucidating the pathogenesis of liver diseases and developing clinical therapeutic approaches.

关 键 词：肝窦内皮细胞 肝脏疾病 药物治疗 

分 类 号：R575[医药卫生—消化系统]